fabianhulpia

Scientist Medicinal Chemistry @JanssenBelgium
Previously Postdoc @GhentUniversity

[fabianhulpia @fabianhulpia]

Cool to see our paper on GI-restricted PRMT5 inhibitors now incorporated in a JMedChem issue! Particularly as it is on the journal's front cover
@ACSPublications #MyACSCover

[Santiago Cañellas @SantiCanellasR]

Interested in #HighThroughput #Photochemistry including #HTE and #Automated #LibrarySynthesis in Batch and Flow? Take a look at this pre-print!

Bug shout-out to everyone! 🤖🥼

#JNJ #Automation #Photochemistry #Photocatalysis #ParallelMedicinalChemistry

https://t.co/ffvh828q91

[fabianhulpia @fabianhulpia]

@KrolsSimon @MuhammadRishfi @kdurinck Nice!

[fabianhulpia @fabianhulpia]

@D_B_McConnell How about Sofosbuvir in the infectious disease area?

[Hilmar Weinmann @HilmarWeinmann]

Our Discovery Process Research Team at the interface between Medicinal Chemistry and Chemical Process R&D is growing further! Exciting opportunity for creative organic chemists. Check the link below. https://t.co/knhjMwzuTy

[fabianhulpia @fabianhulpia]

@DennisWhom Erik was first to develop an anti-HIV in vitro screening assay and showed that Holy's acyclic NUC analogues have activity. It was the start of Gilead

[Daniel Wacker @WackerLab]

Sharing our @bioRxivpreprint of “Substrate Binding and Inhibition of the Anion Exchanger 1 Transporter”, in which we reveal how AE1 binds and transports substrates, and how different drugs inhibit the transporter.

[Duc Tran @DucTran23]

Our Switzerland colleagues are looking for an entry level for process R&D (Organic chemistry) #chemjobs https://t.co/XRgmyMwedd

[fabianhulpia @fabianhulpia]

@KRHornberger AZT is such an example, and the group of Chris Meier in Hamburg has developed prodrugs of di- and triphosphates...
https://t.co/IVgsy4Ffvn
A very recent example is this JMC paper: https://t.co/TqVqHMgHK5

[fabianhulpia @fabianhulpia]

@KRHornberger Hi Keith, to complicate matters even further, you have Nuc analogues for which DiPhosphate formation is the RDS

[Johan Neyts @neyts_johan]

Check our paper @NeytsVirology @KU Leuven published in @Nature in which we report on a highly potent pan-serotype dengue inhibitor with unprecedented potency in infection models. 
https://t.co/whXSPEQi10

[Synthesis Workshop @MatthewHorwitz1]

Join the 2021 Synthesis Workshop #NamedReactionChallenge! To participate, make a poster about a named reaction and post it on Twitter using #NamedReactionChallenge. Let's collect and share knowledge together!

RTs appreciated, example below. #RealTimeChem #ChemTwitter

[Baran Lab @BaranLabReads]

Today we report @ChemRxiv a practical method to obtain C–4 alkylated pyridines with exquisite site-selectivity in collaboration with @GodineauEdouard of @Syngenta using simple Minisci decarboxylation: https://t.co/HpZevQpKbk

[Baran Lab @BaranLabReads]

In 2016, with @EastgateMartin and the @bmsnews team we set out to simplify the way Oligonucleotides therapeutics (OTs) are made. Access to a 3-10-3 LNA/DNA gapmer with 4 different P-linkages had pushed the limits of known chem. Today we report a solution: https://t.co/hSsZXFg3DJ

[Baran Lab @BaranLabReads]

Today we reveal (https://t.co/y0lSxQ23nU) a new approach to controlling chemoselectivity in synthesis. Imagine, if by simply changing the waveform by which electrical current were delivered one could control the selectivity of reduction of a functionally rich peptide like this?

[Scientific Update @SciUp]

Pyrylium salts- kryptonite for the Sandmeyer reaction? find out on our blog... https://t.co/Qd8GIMBLLd

[Ingo Hartung @HartungIngo]

Twitter-mediated experimental peer review of the not-so-Pd-free #Suzuki-Miyaura coupling recently reported in @NatureCatalysis. A shout out to @bedcatalysis and partners @BristolChem @pavel_kulyabin @durham_uni https://t.co/w0pCGNCpBK @ChemRxiv

[fabianhulpia @fabianhulpia]

@GusTheChemist have you considered 2D NMR techniques of the heteroatom nuclei?
H-N HSQC/HMBC and F-C based ones? Or 2D F NOESY?